Saturday 17 October 2026
Export MRAI’s income statement to Excel — free account
Marpai, Inc.
MRAI Healthcare Healthcare Plans
Marpai, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.1 million, down 35.8% from fiscal 2024. In the quarter to June 2026, revenue fell 10.5%, EPS grew 35.7%, free cash flow fell 27.7% and total debt fell 20.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.13
0.06
−1.88%
Follow MRAI
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 4 | 2 | 2 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | 0.00 | 0.64 | 0.33 | 0.39 | 0.60 |
Altman Z-Score |
— | — | — | 0.71 | (2.22) | (5.11) | (14.72) | (18.80) |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | 0.51 | (5.41) | (14.92) | (40.87) | (52.88) |
Beneish M-Score |
— | — | — | — | 1.03 | (4.46) | (5.78) | (6.73) |
P/Operating CF |
— | — | — | (8.38) | (0.79) | (28.46) | (2.34) | (2.30) |
P/B ratio |
— | — | — | 1.49 | 2.56 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | 2.02 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | 0.00 | (0.06) | 0.08 | 0.38 | 1.04 |
EV/EBITDA |
— | — | — | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | (1.88) | 0.04 | (0.19) | (0.70) | (2.53) |
EV/FCF |
— | — | — | (1.48) | 0.04 | (0.19) | (0.68) | (2.34) |
Quick Ratio |
— | 1.38 | 0.72 | 2.36 | 1.44 | 0.74 | 0.56 | 0.39 |
Current Ratio |
— | 1.46 | 0.82 | 2.42 | 1.53 | 0.82 | 0.63 | 0.40 |
Net Debt/EBITDA |
— | (2.89) | (2.33) | 1.73 | 0.75 | 0.66 | 0.03 | (0.37) |
Debt/Assets |
0.00% | 108.99% | 138.68% | 4.72% | 12.18% | 1.99% | 69.31% | 126.51% |
Debt/Equity |
— | (5.29) | (2.59) | 0.07 | 0.99 | (0.05) | (0.32) | (0.42) |
Asset Turnover |
— | 0.00 | 0.00 | 0.56 | 0.52 | 0.91 | 1.26 | 1.52 |
Operating CF/Net income |
— | 0.00 | 0.50 | 0.68 | 1.33 | 0.55 | 0.69 | 0.45 |
Capex/Depreciation |
— | 0.00 | (4.59) | (0.83) | (0.23) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | (6.46) | (37.13) | (101.04) | (18.32) | (8.15) | (4.19) |
| — | 76.57% | 177.04% | (121.97%) | (147.69%) | 787.33% | 107.36% | 54.95% | |
| — | (78.91%) | (71.82%) | (63.01%) | (56.23%) | (70.45%) | (99.14%) | (139.26%) | |
ROIC |
— | 0.00% | (56.22%) | (169.14%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (445.51%) | 1,413.74% | (95.51%) | (247.73%) | 913.63% | 311.76% | 107.83% |
Average Days of Receivables |
— | 0.00 | 0.00 | 8.09 | 27.27 | 18.59 | 18.22 | 19.70 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 12.19% | 15.23% | 3.53% | 0.10% | 0.04% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 91.52% | 79.11% | 69.37% | 51.82% | 67.57% |
Intangible Assets out of Total Assets |
0.00 | 0.77 | 0.58 | 0.18 | 0.24 | 0.26 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 8.65% | 12.76% | 5.65% | 11.21% | 19.97% |
Graham Net Nets |
— | — | — | 0.28 | (1.10) | (2.32) | (2.62) | (3.03) |
Graham Number |
— | — | — | 0.00 | 0.00 | 13.85 | 10.59 | 6.33 |
Earnings Yield |
— | — | — | (39.80%) | (169.03%) | (253.45%) | (217.89%) | (150.79%) |
Free Cash Flow Yield |
— | — | — | (31.15%) | (234.65%) | (134.95%) | (143.88%) | (73.38%) |
Revenue per Share |
— | 0.00 | 0.00 | 5.65 | 4.81 | 5.34 | 2.45 | 1.04 |
Operating CF per Share |
— | 0.00 | (3.21) | (4.29) | (6.96) | (2.27) | (1.32) | (0.43) |
Capex per Share |
— | 0.00 | (1.92) | (0.69) | (0.19) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
— | 0.00 | (5.13) | (4.98) | (7.16) | (2.26) | (1.32) | (0.43) |
Cash per Share |
— | 0.05 | 2.99 | 10.30 | 4.57 | 1.94 | 0.80 | 0.52 |
Shareholders Equity per Share |
— | (0.17) | (5.76) | 11.79 | 1.21 | (1.93) | (2.41) | (1.87) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.17) | (5.76) | 11.79 | 1.21 | (1.93) | (2.41) | (1.87) |
Free Cash Flow |
— | 0.00 | (3.12) | (12.54) | (36.20) | (15.72) | (15.16) | (7.45) |
Working Capital |
— | 0.09 | (0.47) | 15.85 | 9.18 | (3.76) | (7.08) | (15.36) |
Capital Expenditures |
— | 0.00 | (1.17) | (1.74) | (0.97) | 0.03 | — | — |
Net Current Asset Value |
— | (4.82) | (7.85) | 12.50 | (17.28) | (28.03) | (28.69) | (33.13) |
EV/EBIT |
— | — | — | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.12 | 0.04 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.00 | 1.30 | 2.35 | 2.75 | 13.78 | 0.00 | 0.00 |
Cash ROIC |
— | 0.00% | (42.25%) | (21.71%) | (102.46%) | (2,291.84%) | 158.71% | 75.92% |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 68.53 | 22.81 | 20.03 | 17.08 | 15.19 |
Accounts Payable Turnover |
— | 0.65 | 1.39 | 15.82 | 13.27 | 7.94 | 4.92 | 3.93 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 229.21 | 418.89 | 39.94 | 31.05 | 70.01 | 59.52 | 100.52 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.06 | 0.06 | 0.21 | 1.07 | 1.86 | 1.65 | 1.19 |
Average Payables |
— | 0.11 | 0.11 | 0.65 | 1.29 | 3.05 | 3.88 | 3.39 |
Average Assets |
— | 2.12 | 5.39 | 25.37 | 47.08 | 40.81 | 22.28 | 11.89 |
Average Common Equity |
— | (2.18) | (2.18) | 13.11 | 17.92 | (3.65) | (20.57) | (30.14) |
Columns are period end dates